Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics Inc exhibits a promising financial outlook, with projected risk-adjusted sales expected to reach $171 million in 2026 and peak sales estimated at $1.9 billion by 2031. The company has notably increased its market penetration estimate for relacorilant in ovarian cancer from 20% to 25%, fueled by robust survival data and favorable FDA approval outcomes. Additionally, the anticipated launch of relacorilant, coupled with a dedicated sales force, underscores the company's strategic position to capitalize on market opportunities in oncology and beyond.

Bears say

Corcept Therapeutics's stock outlook appears negative due to several fundamental issues, including a significant decline in the 12-month price target from $105 to $67 per diluted share, reflecting concerns over the company's future revenue potential and increased execution risk. The Complete Response Letter for relacorilant in Cushing’s syndrome has contributed to a sharp decline in share value, alongside anticipated pricing pressure on Korlym sales due to court rulings, which may further impact financial performance in 2026. Additionally, management turnover raises concerns regarding the continuity and progress of clinical development, potentially leading to further adverse effects on share performance in a volatile political and regulatory landscape.

Corcept Therapeutics (CORT) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 4 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.